Updated regularly — Updated June 2025
Getting Mounjaro or Wegovy on the NHS: your honest, complete 2025 guide
The most common question we receive is: "Can I get Mounjaro on the NHS?" The honest answer is: possibly — but it depends on where you live, your BMI, your health conditions, and how quickly your local NHS is implementing new guidance. Here's the complete picture, including what to do if NHS access isn't yet available to you.
The short answer
Both Mounjaro (TA1026) and Wegovy (TA875) have NICE approval for NHS use, but practical access through NHS GPs remains very limited as of 2025. The primary NHS route is through a Tier 3 specialist weight-management service — requiring a GP referral, specific BMI criteria, and prior engagement with a lifestyle programme. A postcode lottery applies: access varies significantly by Integrated Care Board. Many people currently access these medications privately while waiting for NHS rollout to reach their area.
NICE approvals: what they actually mean in practice
NICE — the National Institute for Health and Care Excellence — has approved both Mounjaro and Wegovy for NHS use following detailed reviews of clinical evidence. NICE approval means these treatments are considered clinically effective and cost-effective enough to be funded by the NHS, under certain conditions.
Mounjaro was approved under Technology Appraisal TA875 in 2023.
Wegovy was approved under Technology Appraisal TA875, also in 2023.
However, NICE approval does not mean immediate universal NHS availability. What it means is that NHS England must commission the treatment — but implementation happens in stages, through specialist services, and according to local funding decisions by Integrated Care Boards. The gap between "NICE approved" and "your GP can prescribe it" can be years.
Why the gap exists
NHS England has to develop commissioning frameworks, fund services, train staff, and manage demand before these treatments are widely available. Additionally, NICE approval for these medications specifies use through specialist services — not routine GP prescribing — which requires an entirely new service infrastructure in many areas.
NHS eligibility criteria — exactly who qualifies
The following table summarises current NHS eligibility criteria based on NICE TA1026 (Mounjaro) and TA875 (Wegovy) guidance and NHS England commissioning frameworks.
| Criteria | Mounjaro (TA1026) | Wegovy (TA875) |
|---|---|---|
| BMI threshold | ≥35 kg/m² (or 30–34.9 + comorbidities) | ≥35 kg/m² (or 30–34.9 + comorbidities) |
| Comorbidities (for lower BMI) | Type 2 diabetes, hypertension, dyslipidaemia, cardiovascular disease, sleep apnoea | Same as Mounjaro |
| Prior treatment | Non-surgical weight management interventions have not achieved adequate response | Same |
| Service setting | Specialist weight-management service (Tier 3) | Tier 3 or NHSE-approved primary care setting (limited) |
| Monitoring | Regular review of weight response; discontinue if <5% loss at 16 weeks (5mg dose) | Regular review; discontinue if insufficient response |
| Age | Adults (18+) | Adults (18+) |
Source: NICE TA1026 (Mounjaro), NICE TA875 (Wegovy), NHS England commissioning guidance 2024. Eligibility criteria subject to local ICB implementation decisions. Always confirm with your GP or specialist service.
Lower BMI eligibility for certain ethnic backgrounds
NICE guidance acknowledges that people from South Asian, Chinese, and other Asian backgrounds may have significantly increased health risks at lower BMI thresholds. Some specialist services apply lower BMI cut-offs for these groups. Ask your GP whether this is relevant to your assessment.
What is a Tier 3 weight-management service?
The NHS uses a tiered approach to weight management. Understanding where Tier 3 fits helps explain why NHS access to Mounjaro and Wegovy is limited.
| Tier | Service | Typical provision |
|---|---|---|
| Tier 1 | Universal services | Public health campaigns, healthy eating advice, community exercise programmes |
| Tier 2 | Primary care-level interventions | GP advice, structured weight management programmes (e.g. NHS Weight Management Programme), pharmacist input |
| Tier 3 | Specialist multidisciplinary services | Specialist physician, dietitian, psychologist, physical activity specialist. Intensive programme over several months. Pharmacological treatment (including Mounjaro and Wegovy) may be offered here. |
| Tier 4 | Bariatric surgery | Weight-loss surgery (gastric band, sleeve, bypass) in hospital setting |
A Tier 3 service is not simply a prescription clinic. It is a proper multidisciplinary clinical programme involving a specialist physician, a dietitian, a psychologist (or access to psychological support), and a physical activity specialist. The programme typically lasts several months before pharmacological treatment is considered.
To access a Tier 3 service, you need a GP referral. Your GP will assess whether you meet the criteria and refer you to your local service — if one exists in your ICB area.
The postcode lottery — and how to check your area
Access to NHS-funded Mounjaro and Wegovy through Tier 3 services varies enormously depending on where you live. Some Integrated Care Boards (ICBs — formerly Clinical Commissioning Groups) have moved quickly to commission comprehensive Tier 3 services and are now prescribing these medications. Others have not yet done so, either because of funding constraints or because service infrastructure is still being developed.
This is what's known as the "postcode lottery" — your access to the same NHS-approved treatment depends significantly on your geography.
How to find out about provision in your area
- Ask your GP directly whether your ICB has commissioned Tier 3 weight-management services and whether NHS Mounjaro is available through them
- Search for your ICB's website and look for weight management commissioning documents
- NHS England publishes commissioning guidance updates — search for your ICB by name at england.nhs.uk
- Some ICBs publish waiting time information for specialist weight management referrals
What to do if no service exists near you
If your ICB has not commissioned a Tier 3 service, you may not be able to access NHS Mounjaro or Wegovy in the immediate future. You can: ask your GP to advocate for you with the ICB; contact your local NHS patient experience team; or consider private prescription if you cannot wait. See our section below on private options.
The NHSE primary care pilot
In addition to Tier 3 services, NHS England has been running a limited primary care pilot for Mounjaro (and some semaglutide) prescribing. This pilot provides access through a smaller number of NHS primary care settings, with a slightly different eligibility model.
As of June 2025, this pilot remains geographically limited. Not all GPs or practices are participating, and places on the pilot are limited. If you live in an area where the pilot is active, your GP will know about it and can tell you whether you might be eligible to participate.
The pilot is expected to inform a wider primary care rollout over the coming years — but timelines remain uncertain, and we would not advise depending on it as an access route unless your GP has confirmed active participation in your area.
How to talk to your GP about Mounjaro or Wegovy
Many people tell us they feel nervous about raising Mounjaro or Wegovy with their GP — worried about being judged, dismissed, or told the medication isn't appropriate. We want to help you feel prepared, because this conversation is worth having.
- Know your BMI before you goCalculate your BMI in advance using our widget below. If your BMI is 35+ (or 30+ with health conditions like type 2 diabetes or high blood pressure), you have a strong basis for the conversation.
- Mention NICE TA875 by nameGPs who are unfamiliar with GLP-1 prescribing will find it easier to engage if you can reference the NICE technology appraisal. "I've been reading about NICE TA1026 for Mounjaro — can you tell me whether there's a Tier 3 service available through our ICB?" This shows you've done your research.
- Describe your history with weight managementTier 3 eligibility typically requires evidence of prior engagement with lifestyle interventions. Being able to describe what you've already tried — dietary approaches, activity changes, other programmes — strengthens your case for a referral.
- Mention relevant health conditionsIf you have conditions that are directly affected by your weight — type 2 diabetes or pre-diabetes, hypertension, dyslipidaemia, sleep apnoea, or cardiovascular risk — these strengthen your eligibility case and are worth raising explicitly.
- Ask about both routesAsk whether a Tier 3 referral is possible, and whether your practice is participating in the NHSE primary care pilot. If neither is immediately available, ask what would help your case or when NHS provision in your area is expected to improve.
If your GP seems unfamiliar or reluctant
Some GPs, particularly those who trained before GLP-1 therapies became widely available, may be less familiar with the current NICE guidance. This is not a reflection on you. Providing the NICE TA number, asking the practice to check with their clinical lead, or requesting a second opinion are all reasonable steps. You can also see our dedicated guide to talking to your GP.
Check if you might meet NHS eligibility criteria
This tool gives a general indication only — it is not a clinical assessment, and actual eligibility depends on your full medical history and local ICB commissioning decisions.
What if NHS access isn't available to you yet?
If you don't currently qualify for NHS Mounjaro or Wegovy, or if there's no Tier 3 service in your area, private prescription through a GPhC-registered UK pharmacy is an alternative that many people are using.
Private prescription means paying out of pocket for both the consultation and the medication. Costs vary by dose and pharmacy, but typical monthly costs range from around £149 to £275 depending on dose (see our Mounjaro cost guide and Wegovy cost guide for detailed breakdowns).
Before using any private service, our guide to UK pharmacy types explains the differences between independent prescribers, PGD services, CQC-regulated clinics, and large chain pharmacies — and how to choose safely. Always verify GPhC registration at pharmacyregulation.org. Two independent pharmacies whose community work we greatly admire: (Mounjaro) and (Wegovy). We have no commercial relationship with either.
Will NHS access to Mounjaro and Wegovy improve?
The honest answer is: yes, in time — but the pace of rollout is uncertain. NHS England has committed to expanding access to specialist weight-management services, and the NHSE primary care pilot is designed to build the evidence base for a broader primary care rollout.
Realistically, full NHS availability through GPs (similar to how statins or blood pressure medications are routinely prescribed) is probably several years away for most people. The NHS system requires: funding commitments by ICBs, workforce training, service commissioning, demand management, and integration with existing clinical pathways.
What is certain is that both medications will become more widely available on the NHS over time, as the clinical case is already firmly established. The NICE approvals are in place. The question is one of implementation pace and local funding.
Frequently asked questions
As of June 2025, most NHS GPs cannot prescribe Mounjaro directly for weight management because NHS commissioning specifies use through specialist Tier 3 services. However, GPs can prescribe it privately (outside the NHS). Some GPs participating in the NHSE primary care pilot can prescribe it under that specific programme. Ask your GP directly about what's available in your area.
Waiting times vary enormously by area. Where Tier 3 services exist, waiting times can range from a few weeks to over a year. Your GP will know the current waiting time for your local service if one is available. Where no service has been commissioned, there is no waiting list — because there is no service to wait for.
If you access Mounjaro through an NHS Tier 3 service, the medication is free at point of use — though standard NHS prescription charges may apply if you don't hold an exemption certificate (e.g. pre-payment certificate, benefits-based exemption, or medical exemption). Contact your pharmacist or service to understand the charges applicable to you.
In principle, yes — there is no rule that prevents you from switching from private to NHS provision once NHS services become available to you. However, NHS Tier 3 services will conduct their own assessment and your private history may or may not factor into it. Discuss your full history (including private treatment) honestly with your GP when seeking an NHS referral.
Possibly, if your BMI is 30–34.9 and you have at least one significant weight-related comorbidity. The NICE criteria allow for lower BMI eligibility with type 2 diabetes, hypertension, cardiovascular disease, dyslipidaemia, or sleep apnoea. Additionally, people from South Asian and East Asian backgrounds may have eligibility assessed at lower BMI thresholds due to differential cardiovascular risk. Discuss this specifically with your GP.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Eligibility criteria and service availability may vary by ICB and may change as NHS commissioning develops. Always consult your GP for advice specific to your circumstances. Information reflects publicly available NICE and NHS England guidance as of June 2025. References: NICE TA1026; NICE TA875; NHS England commissioning guidance 2024; NHS weight management service framework. Full disclaimer →